Moleculin Biotech Inc expected to post a loss of 56 cents a share - Earnings Preview

Moleculin Biotech

06/05/2025 15:03

Moleculin Biotech Inc MBRX.OQ MBRX.O is expected to show no change in quarterly revenue when it reports  results on May 8 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Moleculin Biotech Inc is for a loss of 56 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 1.9% in the last three months. ​

Wall Street's median 12-month price target for Moleculin Biotech Inc is $8.00​, above​ its last closing price of $1.04. ​​​

This summary was machine generated May 6 at 14:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)